RxDoctor Payments DataLook up a doctor →

Gabriel Hernandez, MD

Internal Medicine · Jackson, MSNPI 1790071645

Payments from drug & device makers

$195,920in general payments, 2019–2025

Across 692 payments — averaging $283.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$87K
  • Penumbra, Inc.$26K
  • AstraZeneca$24K
  • Stryker$24K
  • Abiomed$10K
  • Livanova USA, Inc.$10K
  • plus $15K from 40 others

What the payments were for

  • Consulting fees$5,40013%
  • Speaking & faculty fees$6,77317%
  • Travel & lodging$8,30721%
  • Food & beverage$19,83649%
  • Education$1960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$195,920 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$135,057
Medicare patients
335
Services billed
1,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan96$71,022
FarxigaDapagliflozin Propanediol41$30,584
JardianceEmpagliflozin19$17,382
EliquisApixaban27$15,654
Cefepime Hcl11$2,045
Metoprolol Succinate73$1,048
Spironolactone66$741
Carvedilol87$609
Bumetanide32$545
Losartan Potassium55$413
Isosorbide Dinitrate18$392
Digoxin11$354
Rosuvastatin Calcium17$281
Hydralazine Hcl20$224
Isosorbide Mononitrate ErIsosorbide Mononitrate34$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$504$71,02296 claims
AstraZenecaFarxiga$24,489$30,58441 claims
Boehringer IngelheimJardiance$463$17,38219 claims
PfizerEliquis$599$15,65427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →